ARTHRITIS may have met its match, in the form of the llama immune system. Antibodies similar to ones originally discovered in camels and llamas have helped to heal moderate to severe arthritis in a small trial.
The antibodies have inspired the design of a drug, ALX-0061, that blocks a receptor for interleukin 6. This signalling molecule amplifies inflammation, leading to sore and swollen joints. The symptoms ease once the receptor is blocked.
In the trial, 24 patients received one of three unchanging doses of ALX-0061 for six months. Another group received a placebo. Sixty-three per cent of those given the drug saw their symptoms practically vanish when measured using a standard metric, the DAS28 scale, which evaluates symptoms in 28 joints. This figure is more than twice the 30 per cent remission rate seen with the current "gold-standard" rival treatment Actemra (tocilizumab). Tocilizumab also targets interleukin 6, but it is based on a normal-sized mammalian antibody.
The remission rate was even higher – 75 per cent – for the eight patients given one of the three doses: 3 milligrams per kilogram of body weight administered once every four weeks. "These data suggest that out of every 10 patients, seven to eight could experience rapid, durable responses to their symptoms," says Josi Holz, the chief medical officer of Ablynx, in Ghent, Belgium, which released its results on 13 February.
According to Ed Moses, CEO of Ablynx, it could be the tiny size of the molecule – one-fifth the usual size – that gives it the edge over existing antibody-based treatments. "It potentially gives far faster and deeper penetration of diseased joints," he says.
Other researchers caution against over-optimism because the trial was short and small. "If the results are repeated in randomised, controlled, double-blinded studies, then they would be very impressive," says David Scott, chief medical adviser to the UK's National Rheumatoid Arthritis Society.
To take ALX-0061 forward, Ablynx is now looking for a partner to help finance such a larger, decisive trial.
This article appeared in print under the headline "Llama-inspired drug relieves arthritic pain"
If you would like to reuse any content from New Scientist, either in print or online, please contact the syndication department first for permission. New Scientist does not own rights to photos, but there are a variety of licensing options available for use of articles and graphics we own the copyright to.
All comments should respect the New Scientist House Rules. If you think a particular comment breaks these rules then please use the "Report" link in that comment to report it to us.
If you are having a technical problem posting a comment, please contact technical support.
Synthetic llama antibodies soothe arthritis pain
This article
Synthetic llama antibodies soothe arthritis pain
can be opened in url
http://newsvolunteer.blogspot.com/2013/02/synthetic-llama-antibodies-soothe.html
Synthetic llama antibodies soothe arthritis pain
